A research group from the Korea Advanced Institute of Science and Technology (KAIST) and biotechnology firm Neogenlogic announced that it has built an artificial intelligence system designed to create personalized cancer vaccines.
The model identifies patient-specific neoantigens that can train the immune system to prevent the disease from returning. Neogenlogic reported the technology has been tested against large genomic datasets and integrated into its DeepNeo platform.
Meanwhile, Professor Choi Jung-kyoon of KAIST said the team plans to submit an investigational new drug application to the US Food and Drug Administration, aiming for clinical trials in 2027.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.